ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
Systematically Engineering for Efficient Production of 3-Methyl-1-Butanol in Escherichia coli.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
3-Methyl-1-butanol (3-MB), a promising next-generation biofuel, has garnered significant interest owing to its superior combustion characteristics and fuel compatibility. However, current 3-MB biosynthesis faces major challenges, including low production efficiency and severe toxicity-induced growth inhibition, which significantly limit its industrial feasibility. In this study, we systematically developed an integrated metabolic engineering approach for high-level 3-MB production in Escherichia coli. Through semi-rational engineering of the rate-limiting enzyme dihydroxyacid dehydratase (DHAD), combined with molecular dynamics simulations, we identified and addressed previously unrecognized catalytic bottlenecks. The engineered strain exhibited a 32.3-fold increase in 3-MB production, reaching 2.20 g/L in shake-flask cultures. Subsequent adaptive laboratory evolution further improved strain robustness, while genomic analysis revealed novel regulatory targets for metabolic optimization. In a scaled-up bioreactor fermentation system, the final strain achieved a record titer of 6.24 g/L, representing the highest reported titer for engineered microbial systems. This work not only establishes a scalable platform for 3-MB biosynthesis but also provides a modular engineering framework applicable to other advanced biofuels.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.